NCT07710417 FLOAT for Healthcare PTSS
| NCT ID | NCT07710417 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Laureate Institute for Brain Research, Inc. |
| Condition | Posttraumatic Stress Symptoms |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-06-10 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2026-06-10 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This early-stage pilot trial aims to examine the feasibility, tolerability, and safety of Floatation-REST, or Reduced Environmental Stimulation Therapy via floatation in frontline healthcare workers, first responders, and emergency medical personnel who experience post-traumatic stress symptoms.
Eligibility Criteria
Inclusion Criteria: 1. Work-related post-traumatic stress dysfunction as measured by either of the following inclusion pathways: (A) PTSS Pathway: PCL-5 greater than or equal to 20, OR meets criteria for full or partial PTSD on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criteria A + at least 2 B-E Criteria) OR (B) Functionally Anchored Pathway: evidence of work-related trauma exposure on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criterion A) or Life Events Checklist-5, and at least one of the following: Moral Injury and Distress Scale greater than or equal to 27, Sheehan Disability Scale greater than or equal to 5 on at least 1 of the 3 subscales, high or very high level of perceived stress (measured by PhenX Perceived Stress Scale greater than or equal to 16). 2. First responder or other emergency medical personnel 3. Ability to read, speak and understand English 4. Capable of providing consent Exclusion Criteria: 1. History of neurological conditions 2. Skin conditions or open wounds 3. DSM-5 diagnosis of psychotic spectrum disorders, obsessive-compulsive disorder, bipolar disorder, severe substance use disorder, or eating disorder 4. Inability to lay comfortably in a shallow pool of water 5. Failure to adhere to "pre-float checklist" 6. Breathalyzer test positive for alcohol or a drug-positive urine test 7. Unwillingness to provide consent or complete major aspects of protocol 8. MRI contraindications 9. Unstable medical diagnoses 10. Pregnancy 11. Evidence of inability to comply with study procedures based on experimenter judgement 12. Change in the dose or prescription of a medication within the 6 weeks before enrolling in the study that could affect brain functioning (e.g., anxiolytics, antipsychotics, antidepressants, benzodiazepines, or mood stabilizers)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07710417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Posttraumatic Stress Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07710417 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07710417 currently recruiting?
Yes, NCT07710417 is actively recruiting participants. Contact the research team at ataren@laureateinstitute.org for enrollment information.
Where is the NCT07710417 trial being conducted?
This trial is being conducted at Tulsa, United States.
Who is sponsoring the NCT07710417 clinical trial?
NCT07710417 is sponsored by Laureate Institute for Brain Research, Inc.. The trial plans to enroll 15 participants.